Together, these results proposed that COL8A1 directly interacting with ITGB1 could activate the PI3K-AKT pathway and promote EMT, thereby leading to CRC resistance to oxaliplatin (Fig. 7T). Here, ITGB1 is linked to colorectal carcinoma.